Drug intelligence / Profile preview

pbi-shRNA STMN1 LP

Development stage: Phase 1
Lead developer: Gradalis
Modality: Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intratumoral

Overview

pbi-shRNA STMN1 LP is an investigational RNA interference (RNAi) therapeutic developed by Gradalis, Inc. It consists of a plasmid encoding a bifunctional short hairpin RNA (bi-shRNA) targeting Stathmin 1 (STMN1), encapsulated in a bilamellar invaginated vesicle (BIV) lipoplex for intratumoral delivery. STMN1 is a microtubule-destabilizing protein often overexpressed in various cancers, contributing to tumor progression and resistance to taxane-based chemotherapy. By utilizing a bifunctional shRNA platform—which combines cleavage-dependent (siRNA-like) and cleavage-independent (miRNA-like) pathways—the drug achieves potent and durable knockdown of STMN1. It has been evaluated in a Phase I clinical trial for patients with advanced or metastatic solid tumors.

Other names: pbi-shRNA™STMN1 LPpbi-shRNA STMN1 BIV lipoplex

Targets

STMN1 (Stathmin-1)

Beyond the preview

Go deeper on pbi-shRNA STMN1 LP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pbi-shRNA STMN1 LP.

Explore the full profile